

**L.J. Rubin** acted as a consultant for Aires, Actelion Pharmaceuticals Ltd, Bayer, GeNo, Gilead, GlaxoSmithKline, Lung LLC, Pfizer, United Therapeutics. L.J. Rubin has received honoraria, travel support and fees for participating in monitoring boards, statistical analyses and endpoint committees from Actelion Pharmaceuticals Ltd, and has acted as an expert witness.

**N. Galiè** has acted as a consultant for Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly & Co, GlaxoSmithKline and Pfizer and has received research funding from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly & Co, GlaxoSmithKline and Pfizer. He has also received honoraria for attending symposiums and speaking. He has also acted as an expert witness.

**G. Simonneau** has served as a consultant for Actelion Pharmaceuticals Ltd, GlaxoSmithKline, Eli Lilly, Novartis, Pfizer and United Therapeutics and has received speaker fees from Actelion, GlaxoSmithKline, Eli Lilly and Pfizer.

**V. McLaughlin** acted as a consultant for Actelion Pharmaceuticals Ltd, Bayer, Gilead and United Therapeutics. V. McLaughlin has received research grants/support from Actelion Pharmaceuticals Ltd, Bayer, Novartis and United Therapeutics. V. McLaughlin received honoraria for lectures including speaker's bureaus from Actelion Pharmaceuticals Ltd, Gilead and United Therapeutics. V. McLaughlin received travel support from Actelion Pharmaceuticals Ltd.